Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, announced that CEO Jill C. Milne will participate in a fireside chat at the Jefferies London Healthcare Conference. The presentation is scheduled for November 20th at 12:00pm GMT in London. A webcast will be available live and archived for 30 days on the company's investor website.
Astria Therapeutics (Nasdaq: ATXS), una azienda biofarmaceutica che sviluppa terapie per malattie allergiche e immunologiche, ha annunciato che il CEO Jill C. Milne parteciperà a una chiacchierata informale durante il Jefferies London Healthcare Conference. La presentazione è programmata per il 20 novembre alle 12:00 GMT a Londra. Sarà disponibile un webcast in diretta che verrà archiviato per 30 giorni sul sito web per gli investitori della compagnia.
Astria Therapeutics (Nasdaq: ATXS), una empresa biofarmacéutica que desarrolla terapias para enfermedades alérgicas e inmunológicas, anunció que la CEO Jill C. Milne participará en una charla informal en la Jefferies London Healthcare Conference. La presentación está programada para el 20 de noviembre a las 12:00 PM GMT en Londres. Se dispondrá de una transmisión en vivo que será archivada durante 30 días en el sitio web de inversores de la empresa.
Astria Therapeutics (Nasdaq: ATXS)는 알레르기 및 면역 질환을 위한 치료제를 개발하는 생명공학 회사로, CEO Jill C. Milne이 Jefferies London Healthcare Conference에서 화기애애한 대화에 참여할 것이라고 발표했습니다. 발표는 11월 20일 오후 12시 GMT에 런던에서 개최됩니다. 회사의 투자자 웹사이트에서는 생중계 및 30일 동안 아카이브된 웹캐스트를 이용할 수 있습니다.
Astria Therapeutics (Nasdaq: ATXS), une entreprise biopharmaceutique développant des thérapies pour les maladies allergiques et immunologiques, a annoncé que le PDG Jill C. Milne participera à une discussion informelle lors de la Jefferies London Healthcare Conference. La présentation est prévue pour le 20 novembre à 12h00 GMT à Londres. Un webinaire sera disponible en direct et archivé pendant 30 jours sur le site web des investisseurs de l'entreprise.
Astria Therapeutics (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das Therapien für allergische und immunologische Erkrankungen entwickelt, gab bekannt, dass CEO Jill C. Milne an einem Gespräch im Rahmen der Jefferies London Healthcare Conference teilnehmen wird. Die Präsentation ist für den 20. November um 12:00 Uhr GMT in London geplant. Ein Live-Stream wird verfügbar sein und 30 Tage lang auf der Investorenseite des Unternehmens archiviert.
- None.
- None.
A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff315/atxs/1873536. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113458379/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When is Astria Therapeutics (ATXS) presenting at the Jefferies London Healthcare Conference?
How long will the Astria Therapeutics (ATXS) Jefferies Conference presentation be available for replay?
What type of diseases does Astria Therapeutics (ATXS) focus on developing treatments for?
Who will represent Astria Therapeutics (ATXS) at the Jefferies London Healthcare Conference?
